Clinical trials
Colorectal cancer clinical trials
Cancer of the colon or rectum, often beginning as small growths called polyps. We’re tracking 1,064 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07653685RecruitingPhase 1/Phase 2
Study of a new drug with chemotherapy for advanced colorectal cancer
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07649057Recruiting
Urine Test for Early Colorectal Cancer Detection
This study tests whether a simple urine sample can detect colorectal cancer or precancerous polyps. Researchers want to see if this non-invasive test could help identify people at risk before symptoms develop or catch cancer earlier.
New York, New YorkAges 18 years+ - NCT06612281RecruitingPhase 2
Testing a new screening tool for colorectal cancer in people with negative FIT results
This trial tests a new device called Gixam to see if it can help find colorectal cancer in people who recently had a normal FIT test (a stool test for blood). You may be able to join if you are between 45 and 85 years old and are already scheduled for a routine screening colonoscopy.
Portland, OregonAges 45–85 - NCT07644286RecruitingPhase 2
Pirfenidone and immunotherapy with optional radiation for advanced colorectal cancer
This study tests a combination of three treatments—pirfenidone (an anti-scarring drug), a PD-1 inhibitor (an immunotherapy that helps your immune system fight cancer), and sometimes radiation—for colorectal cancer that has stopped responding to standard treatments. The goal is to see if this combination can slow or shrink your cancer.
Wuhan, HubeiAges 18–75 - NCT06685276RecruitingPhase 2
Combination therapy for advanced colorectal cancer
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
BeijingAges 18–75 - NCT07627191RecruitingEarly Phase 1
GLP-1 drug plus standard chemo for first-line advanced cancers
This trial tests whether adding a GLP-1 receptor agonist (a drug used for diabetes and weight loss) to standard chemotherapy can help people with advanced pancreatic, colorectal, or liver cancer. It is for people who have not yet started treatment for their metastatic disease and have a BMI of 25 or higher.
Tucson, ArizonaAges 18–99 - NCT07621757Enrolling by invitation
Genetic Risk Testing for Colorectal Cancer Screening
This study looks at how genetic risk information can help decide who needs colorectal cancer screening and when. Researchers want to see if testing for genetic risk factors improves screening decisions for people who haven't had a colonoscopy before.
Evanston, IllinoisAges 45–75 - NCT07617610Recruiting
Understanding Treatment Resistance in BRAF-Mutated Colorectal Cancer
This study looks at why some people with a specific type of colorectal cancer (BRAF V600E-mutated) stop responding to targeted drugs over time. Researchers will take small tissue samples before and during your treatment with anti-EGFR antibody and BRAF inhibitor to understand resistance and help improve future treatments.
AarauAges 18 years+ - NCT06405139RecruitingPhase 2
Chemo combo (nanoliposomal irinotecan, oxaliplatin, capecitabine) before surgery for locally advanced colorectal cancer
This trial tests a combination of three chemotherapy drugs (nanoliposomal irinotecan, oxaliplatin, and capecitabine) given before surgery to shrink locally advanced colorectal cancer that cannot be treated with radiation. The goal is to make the tumor removable with a better chance of complete removal (R0 resection).
BeijingAges 18–70 - NCT06711211Recruiting
Digestive cancer registry study
This study collects information from patients with different types of digestive cancers to better understand these diseases and improve future care. It does not test a new treatment, but helps doctors learn more about digestive cancers over time.
Madrid, MadridAges 18 years+ - NCT06718738RecruitingPhase 1
IM96 CAR-T for advanced colorectal cancer
This trial tests a new cell therapy called IM96 CAR-T, which targets a protein (GUCY2C) found on tumor cells. It is for people with advanced colorectal or stomach cancer that has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07589517RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Colorectal Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to fight advanced colorectal cancer that has spread or cannot be surgically removed. The therapy is customized to target specific protein markers on your cancer cells.
Shenzhen, GuangdongAges 18–75 - NCT07577505Recruiting
Histidine supplement to boost immunity in colorectal cancer
This study tests whether taking a histidine supplement (an amino acid building block) alongside standard colorectal cancer treatment helps your immune system fight the cancer better. Researchers want to see if this simple addition can improve outcomes for people with stage II or higher colorectal cancer.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07559825Recruiting
Understanding Early-Onset Colorectal Cancer in Younger Patients
This study looks at colorectal cancer in younger patients who wouldn't normally be screened. Researchers want to understand how this cancer develops in people under the typical screening age.
Dallas, TexasAges 35 years+ - NCT07551596RecruitingPhase 2
Two immunotherapy drugs for colorectal cancer with residual disease
This trial tests a combination of two immunotherapy drugs to see if they can stop colorectal cancer from returning after standard treatment. It is for people who still have cancer DNA in their blood after surgery and/or chemotherapy, which means they are at high risk of the cancer coming back.
New Orleans, LouisianaAges 18 years+ - NCT07545122RecruitingPhase 1
Testing CT-202 for Triple Negative Breast, Colorectal, and Bladder Cancers
This early-stage trial tests a new antibody drug called CT-202 in patients whose cancer has come back after standard treatments. The drug is designed to target cancer cells that have a specific protein called Nectin-4, and may help the immune system fight the cancer.
Wahroonga, New South WalesAges 18 years+ - NCT07537491Recruiting
AI tool to predict surgery outcomes in colorectal cancer
This study uses artificial intelligence to analyze tissue samples from your colorectal cancer surgery to help predict how you'll recover and what your long-term outlook might be. Researchers will examine your tumor tissue under a microscope to build a computer model that could help doctors personalize your care plan.
Brandenburg an der HavelAges 18 years+ - NCT07535021Recruiting
Mandala Art Therapy to Help With Cancer Surgery Recovery
This study tests whether creating mandala art (decorative circular patterns) helps colorectal cancer patients cope better after surgery. Researchers want to see if art therapy reduces stress, builds emotional strength, and improves your ability to handle the surgery and recovery.
SivasAges 18–74 - NCT07542262Enrolling by invitationPhase 2
Low-dose immunotherapy for advanced colorectal and stomach cancer
This study tests a lower dose of immunotherapy in patients with colorectal or stomach cancer that has spread or cannot be removed by surgery. The cancer must have a specific genetic feature (MSI/dMMR). The goal is to see if this approach works well with fewer side effects.
MoscowAges 18 years+ - NCT07525206RecruitingPhase 3
Combination treatment for advanced colorectal cancer
This trial tests a new drug combination for colorectal cancer that has not responded to other treatments. It compares the new drug with a standard treatment to see which is more effective.
Goodyear, ArizonaAges 18 years+ - NCT03941080Recruiting
Study gut bacteria changes in advanced colorectal cancer
This study looks at how gut bacteria (the microbiome) change during treatment for colorectal cancer that has spread or cannot be removed. Researchers hope the findings may help improve understanding of how treatment works and how to tailor care.
AssenAges 18 years+ - NCT07504367Recruiting
AI assistance in tumor treatment meetings
This study tests whether a large language model can help doctors make better decisions in tumor multidisciplinary team meetings. It evaluates junior doctors with specific experience levels.
Guangzhou, GuangdongAges 25–33 - NCT07494201Recruiting
MIMICC study for people with colorectal cancer
This trial is studying patients with colorectal cancer who are scheduled for surgery. Researchers want to learn more about the cancer to improve future treatments.
Candiolo, Torino (TO)Ages 18–75 - NCT06776757RecruitingPhase 1/Phase 2
Sintilimab plus cetuximab and chemo for first-line advanced colorectal cancer
This trial tests a combination of immunotherapy (sintilimab), a targeted therapy (cetuximab), and chemotherapy as a first treatment for advanced colorectal cancer that hasn't spread or come back after earlier treatment. It's for people whose tumors have certain genetic markers (RAS/BRAF wild-type) and show signs of immune activity (PD-L1 or CD8+ TILs).
Shenzhen, GuangdongAges 18–75
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for colorectal cancer?
- Yes. Clin2 currently lists 1,064 recruiting colorectal cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colorectal cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colorectal cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.